Skip to main content
. 2014 Aug 26;307(8):E695–E702. doi: 10.1152/ajpendo.00253.2014

Fig. 4.

Fig. 4.

Angiogenic proteome expression by PDR vitreous/aqueous-treated CD34+ cells. Supernatants were collected and probed with antibody arrays in duplicate, and cytokine levels were determined by a Human Angiogenesis Array Proteome profiler. A: map of the 55 angiogenesis-related proteins detected on the membranes is shown; highlighted circles are positive controls, and the observed proteins in this study are highlighted in bold in the table at bottom. B: differences in angiogenic protein expression between control and PDR vitreous-treated conditioned mixture. C: differences in angiogenic protein expression between control and PDR vitreous without exposure to CD34+ cells. D: differences in angiogenic protein expression between control and PDR aqueous treated CD34+. E: differences in angiogenic protein expression between control and PDR aqueous without exposure to CD34+ cells. *P < 0.05, significant difference compared with corresponding control; data were analyzed by Student's t-test and are represented as error bars ± SE. ADAMTS-1, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 1; ANG, angiogenin; Ang-1 and -2, angiopoietin-1 and -2, respectively; AR, amphiregulin; CXCL4 and -16, chemokine 4 and 16, respectively; TF, coagulation factor III; CD26, dipeptidyl peptidase IV; EGF, endothelial growth factor; PK1, prokineticin 1; CD105, endoglin; ET-1, endothelin-1; FGF-1, fibroblast growth factor acidic-1; FGF-2 and -4, fibroblast growth factor basic-2 and -4, respectively; KGF, fibroblast growth factor-7; GDNF, glial cell-derived neurotropic factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HB-EGF, heparin-binding endothelial growth factor; HGF, hepatocyte growth factor; IGFBP-1 and -2, IGF-binding protein-1 and -2, respectively; TGF-β1, transforming growth factor-β1; MCP-1, monocyte chemoattractant protein-1; NRG1-β1, neuregulin-β1; PTX3, pentraxin 3; PD-ECGF, platelet-derived endothelial cell growth factor; PDGF-AA and -AB, platelet-derived growth factor-AA and -AB, respectively; PIGF, placental growth factor; TIMP-1 and -4, tissue inhibitor of metalloproteinase-1 and -4, respectively; TSP-1 and -2, thrombospondin-1 and -2; PAI-1 plasminogen activator inhibitor-1; uPA, u-plasminogen activator, VEGF-C, vascular endothelial growth factor-C.